RxDoctor Payments Data

Robert Weaver

Medical Oncology · Houston, TXNPI 1720395064

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Beigene USA, Inc.. That places this record below the midpoint for medical oncology clinicians in TX, where the typical reported total is $4,372.

$52in general payments, 2019–2025

Across 2 payments — averaging $25.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Beigene USA, Inc.$52
$1,028,574in research payments, 2019–2025

Across 41 payments — averaging $25,087 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Mallinckrodt LLC$262K
  • Mylan Pharmaceuticals Inc.$219K
  • Apotex Inc.$207K
  • BD$204K
  • GSK$74K
  • DPT Laboratories, Ltd.$63K

What the payments were for

  • Food & beverage$52100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Beigene USA, Inc.2$52

How this compares

$52 in reported general payments places this provider in the 5th percentile of 495 medical oncology providers in Texas.

See all medical oncology providers in Texas →

Other medical oncology in Houston

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →